TROP2 CAR/IL-15 NK Cells for Stomach Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
The goal of this clinical research study is to study the recommended dose of TROP2 CAR/IL-15 TGFBR2 KO NK cells that can be given intraperitoneally (infused directly into the stomach area) to participants with adenocarcinoma of the stomach that has spread to the peritoneum. The safety and effectiveness of this treatment will also be studied.
Who Is on the Research Team?
Brian D Badgwell, MD
Principal Investigator
UT MD Anderson
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Dose Finding Phase (Ph1)
Participants receive TROP2 CAR/IL-15 TGFBR2 KO NK cells to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D)
Dose Expansion Phase (Ph2)
Participants receive TROP2 CAR/IL-15 TGFBR2 KO NK cells at the RP2D to further evaluate safety and efficacy
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- TGFBR2 KO CAR27/IL-15 NK cells
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Treatment will be adminstered on an inpatient basis.
Find a Clinic Near You
Who Is Running the Clinical Trial?
M.D. Anderson Cancer Center
Lead Sponsor
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.